Does Placebo Response Differ between Objective and Subjective Measures in Children with Attention-Deficit/Hyperactivity Disorder?

References

• . Flint A. A contribution toward the natural history of articular rheumatism, consisting of a report of thirteen cases treated solely with palliative measures. Am J Med Sci. 1863;46:17–36
   Google Scholar
• . Jellinek EM. Clinical tests on comparative effectiveness of analgesic drugs. Biometrics. 1946;2:87–91
   PubMed Web of Science ®Google Scholar
• . Lilienfeld AM. The Fielding H. Garrison Lecture: Ceteris paribus: the evolution of the clinical trial. Bull Hist Med. 1982;56:1–18
   PubMed Web of Science ®Google Scholar
• . Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455–463
   PubMed Web of Science ®Google Scholar
• . Emanuel EJ, Miller FG. The ethics of placebo-controlled trials: a middle ground. N Engl J Med. 2001;345(12):915–919
   PubMed Web of Science ®Google Scholar
• . Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol. 2000;95(7):1637–1643
   Google Scholar
• . Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331(6):394–398
   PubMed Web of Science ®Google Scholar
• . Rothman KJ. Declaration of Helsinki should be strengthened. BMJ. 2000;321(7258):442–445
   PubMed Web of Science ®Google Scholar
• . Enserink M. Bioethics. Helsinki's new clinical rules: fewer placebos, more disclosure. Science. 2000;290(5491):418–419
   Google Scholar
• . Bienenfeld L, Frishman W, Glasser SP. The placebo effect in cardiovascular disease. Am Heart J. 1996;132(6):1207–1221
   Google Scholar
• . World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://wwwwmanet/en/30publications/10policies/b3/17cpdf. Accessed July 23, 2010
   Google Scholar
• . Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology. 2009;112(3):174–177
   PubMed Web of Science ®Google Scholar
• . Khan A, Schwartz K. Design features that affect psychopharmacology trials. Lett Drug Design Discovery. 2005;2:546–550
   Google Scholar
• . Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med. 2000;133(6):464–470
   PubMed Web of Science ®Google Scholar
• . Waschbusch DA, Pelham WE Jr, Waxmonsky J, Johnston C. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2009;30(2):158–168
   PubMed Web of Science ®Google Scholar
• . Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565–590
   PubMed Web of Science ®Google Scholar
• . Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: a review of the recent literature. Pain Pract. 2007;7:4–20
   PubMedGoogle Scholar
• . Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev. 2005;11(2):164–170
   Google Scholar
• . Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Browns WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35(5):743–749
   PubMed Web of Science ®Google Scholar
• . Khan A, Bhat A, Kolts R, Thase ME, Brown W. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther. 2010;16(4):217–226
   PubMed Web of Science ®Google Scholar
• . Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115–127
   PubMed Web of Science ®Google Scholar
• . Kemp AS, Schooler NR, Kalali AH, . What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504–509
   PubMed Web of Science ®Google Scholar
• . Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31(5):369–375
   PubMed Web of Science ®Google Scholar
• . Faraone SV, Short EJ, Biederman J, Findling RL, Roe C, Manos MJ. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol. 2002;5(2):121–129
   Google Scholar
• . Mikami AY, Calhoun CD, Abikoff HB. Positive illusory bias and response to behavioral treatment among children with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2010;39(3):373–385
   PubMed Web of Science ®Google Scholar
• . Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5(8):e166
   Google Scholar
• . Birmaher B, Brent D; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007; 46(11):1503–1526
   PubMed Web of Science ®Google Scholar
• . MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1088–1096
   PubMed Web of Science ®Google Scholar
• . Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997;36(6):754–763
   PubMed Web of Science ®Google Scholar
• . Newcorn JH, Sutton VK, Zhang S, . Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1165–1172
   Google Scholar
• . Batzle CS, Weyandt LL, Janusis GM, Devietti TL. Potential impact of ADHD with stimulant medication label on teacher expectations [published online ahead of print September 22, 2009]. J Atten Disord.
   Google Scholar
• . Johnston C, Ohan JL. The importance of parental attributions in families of children with attention-deficit/hyperactivity and disruptive behavior disorders. Clin Child Fam Psychol Rev. 2005;8(3):167–182
   PubMed Web of Science ®Google Scholar
• . Collett BR, Gimpel GA. Maternal and child attributions in ADHD versus non-ADHD populations. J Atten Disord. 2004;7(4):187–196
   PubMedGoogle Scholar
• . Johnston C, Fine S, Weiss M, Weiss J, Weiss G, Freeman WS. Effects of stimulant medication treatment on mothers' and children's attributions for the behavior of children with attention deficit hyperactivity disorder. J Abnorm Child Psychol. 2000;28(4):371–382
   Google Scholar
• . Johnston C, Reynolds S, Freeman WS, Geller J. Assessing parent attributions for child behavior using open-ended questions. J Clin Child Psychol. 1998;27(1):87–97
   PubMed Web of Science ®Google Scholar
• . Edwards MC, Gardner ES, Chelonis JJ, Schulz EG, Flake RA, Diaz PF. Estimates of the validity and utility of the Conners' Continuous Performance Test in the assessment of inattentive and/or hyperactive-impulsive behaviors in children. J Abnorm Child Psychol. 2007;35(3):393–404
   PubMed Web of Science ®Google Scholar
• . Advokat C, Martino L, Hill BD, Gouvier W. Continuous Performance Test (CPT) of college students with ADHD, psychiatric disorders, cognitive deficits, or no diagnosis. J Atten Disord. 2007;10(3):253–256
   PubMedGoogle Scholar
• . Preston AS, Fennell EB, Bussing R. Utility of a CPT in diagnosing ADHD among a representative sample of high-risk children: a cautionary study. Child Neuropsychol. 2005;11(5):459–469
   PubMed Web of Science ®Google Scholar
• . Teicher MH, Lowen SB, Polcari A, Foley M, McGreenery CE. Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. J Child Adolesc Psychopharmacol. 2004;14(2):219–232
   PubMedGoogle Scholar
• . Teicher MH, Polcari A, McGreenery CE. Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18(3):265–270
   PubMedGoogle Scholar
• . Teicher MH, Polcari A, Foley M, . Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol. 2006;16(4):416–431
   PubMed Web of Science ®Google Scholar
• . Teicher MH, Ito Y, Glod CA, Barber NI. Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry. 1996;35(3):334–342
   PubMed Web of Science ®Google Scholar
• . American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
   Google Scholar
• . Orvaschel H, Puig-Antich J. Schedule for Affective Disorders and Schizophrenia for School-Age Children, Epidemiologic Version, 5th Revision. Fort Lauderdale, FL: Nova Southeastern University; 1994
   Google Scholar
• . Faedda GL, Teicher MH. Objective measures of activity and attention in the differential diagnosis of psychiatric disorders of childhood. Essent Psychopharmacol. 2005;6(5):239–249
   Google Scholar
• . Heiser P, Frey J, Smidt J, . Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate. Eur Child Adolesc Psychiatry. 2004;13(2):100–104
   PubMedGoogle Scholar
• . Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107–115
   Google Scholar
• . Guy W. ECDEU: Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare; 1976
   Google Scholar
• . Pliszka S; Work Group on Quality Issues. AACAP Official Action. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Child Adolesc Psychiatry. 2007; 46(7):894–921
   PubMed Web of Science ®Google Scholar
• . Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257–268
   PubMed Web of Science ®Google Scholar
• . Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):511–518
   PubMed Web of Science ®Google Scholar
• . Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892–1908
   PubMed Web of Science ®Google Scholar
• . Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255–268
   PubMed Web of Science ®Google Scholar
• . Pelham WE Jr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol. 2005;34(3):449–476
   PubMed Web of Science ®Google Scholar
• . Nichols SL, Waschbusch DA. A review of the validity of laboratory cognitive tasks used to assess symptoms of ADHD. Child Psychiatry Hum Dev. 2004;34(4):297–315
   PubMed Web of Science ®Google Scholar
• . Barkley RA. The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol. 1991;19(2):149–178
   PubMed Web of Science ®Google Scholar
• . Conners CK, Epstein JN, Angold A, Klaric J. Continuous performance test performance in a normative epidemiological sample. J Abnorm Child Psychol. 2003;31(5):555–562
   PubMed Web of Science ®Google Scholar
• . Conners CK. The computerized continuous performance test. Psychopharmacol Bull. 1985;21(4):891–892
   PubMed Web of Science ®Google Scholar
• . Kelsey DK, Sumner CR, Casat CD, . Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1–e8
   PubMed Web of Science ®Google Scholar
• . Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–279
   PubMed Web of Science ®Google Scholar
• . Findling RL, Bukstein OG, Melmed RD, . A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(1):149–159
   PubMedGoogle Scholar